{"id":"consolidation-with-brentuximab-vedotin","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Peripheral neuropathy"},{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Brentuximab vedotin is a monoclonal antibody conjugated to the microtubule inhibitor vedotin, which targets CD30-positive cells.","oneSentence":"Antibody-drug conjugate targeting CD30","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:57.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Systemic anaplastic large cell lymphoma"}]},"trialDetails":[{"nctId":"NCT03652441","phase":"PHASE2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2019-11-13","conditions":"Classical Hodgkin Lymphoma","enrollment":14},{"nctId":"NCT06507514","phase":"PHASE1","title":"Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-01","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT07013565","phase":"PHASE2","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2025-08-07","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":20},{"nctId":"NCT03233347","phase":"PHASE2","title":"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-10-13","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT04561206","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-12","conditions":"Relapsed Classic Hodgkin Lymphoma","enrollment":31},{"nctId":"NCT05100056","phase":"","title":"A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-03-08","conditions":"Hodgkin Lymphoma","enrollment":70},{"nctId":"NCT03517137","phase":"PHASE2","title":"Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-08-01","conditions":"Advanced Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT03719105","phase":"EARLY_PHASE1","title":"Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2019-03-01","conditions":"NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma","enrollment":40},{"nctId":"NCT07074457","phase":"NA","title":"Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"CD30+ Peripheral T-cell Lymphoma","enrollment":47},{"nctId":"NCT01868451","phase":"NA","title":"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Hodgkin Lymphoma","enrollment":118},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03057795","phase":"PHASE2","title":"Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-04-03","conditions":"Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT05595447","phase":"PHASE2, PHASE3","title":"Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hospital Regional de Alta Especialidad del Bajio","startDate":"2022-10-18","conditions":"Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult","enrollment":20},{"nctId":"NCT03703050","phase":"PHASE2","title":"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-01-02","conditions":"Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma","enrollment":45},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT04378647","phase":"PHASE2","title":"BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2020-06-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":150},{"nctId":"NCT04776265","phase":"","title":"RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT","status":"UNKNOWN","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-06-01","conditions":"Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT04334174","phase":"PHASE2","title":"Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas","status":"WITHDRAWN","sponsor":"University of Kansas Medical Center","startDate":"2020-05-29","conditions":"T Cell Lymphoma","enrollment":""},{"nctId":"NCT01578967","phase":"NA","title":"Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-04","conditions":"Hodgkin Lymphoma, Adult","enrollment":41},{"nctId":"NCT01805037","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2013-03-05","conditions":"Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma","enrollment":20},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT01476410","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2011-11","conditions":"Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma","enrollment":48},{"nctId":"NCT02243436","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2014-11-11","conditions":"CLASSICAL HODGKIN LYMPHOMA","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":157,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adcetris treatment as consolidation"],"phase":"phase_2","status":"active","brandName":"Consolidation with Brentuximab Vedotin","genericName":"Consolidation with Brentuximab Vedotin","companyName":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","companyId":"grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antibody-drug conjugate targeting CD30 Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}